BridgeBio Oncology Therapeutics, Inc. (BBOT) intrinsic value & 10-year financials
BridgeBio Oncology Therapeutics, Inc. (BBOT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.82
- Market cap
- $87.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -1884.5%
- Free cash flow (FY2025)
- -$114.5M
BBOT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$134.0M | -$4.30 | -$114.5M | — | -5752.9% |
| FY2024 | $6.2K | $7.6M | -$2.38 | -$812.8K | -9453.1% | 1.7% |
| FY2023 | — | -$41.7K | — | — | — | 97.6% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BridgeBio Oncology Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BridgeBio Oncology Therapeutics, Inc. returns on capital have been average, hovering around 13.9% ROIC over the decade.
BridgeBio Oncology Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BridgeBio Oncology Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.